IDEXX Laboratories, Inc. (IDXX) Shares Bought by Goldman Sachs Group Inc.
Goldman Sachs Group Inc. boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 40.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,243,642 shares of the company’s stock after buying an additional 355,939 shares during the quarter. Goldman Sachs Group Inc. owned approximately 1.42% of IDEXX Laboratories worth $200,750,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in IDXX. BlackRock Inc. lifted its holdings in IDEXX Laboratories by 1,967.1% during the 1st quarter. BlackRock Inc. now owns 6,427,027 shares of the company’s stock valued at $993,680,000 after buying an additional 6,116,102 shares in the last quarter. Vanguard Group Inc. lifted its holdings in IDEXX Laboratories by 24.3% during the 1st quarter. Vanguard Group Inc. now owns 8,910,555 shares of the company’s stock valued at $1,377,660,000 after buying an additional 1,740,446 shares in the last quarter. State Street Corp lifted its holdings in IDEXX Laboratories by 38.6% during the 1st quarter. State Street Corp now owns 3,911,739 shares of the company’s stock valued at $604,793,000 after buying an additional 1,089,880 shares in the last quarter. Old Mutual Global Investors UK Ltd. bought a new stake in IDEXX Laboratories during the 2nd quarter valued at about $83,723,000. Finally, Renaissance Technologies LLC lifted its holdings in IDEXX Laboratories by 38.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,351,900 shares of the company’s stock valued at $218,224,000 after buying an additional 376,300 shares in the last quarter. Institutional investors own 87.64% of the company’s stock.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded up 0.73% on Friday, reaching $155.49. 392,762 shares of the company’s stock were exchanged. The stock has a market cap of $13.57 billion, a price-to-earnings ratio of 53.49 and a beta of 0.49. IDEXX Laboratories, Inc. has a one year low of $102.45 and a one year high of $173.01. The firm has a 50 day moving average of $154.86 and a 200-day moving average of $159.27.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.10. The business had revenue of $508.90 million for the quarter, compared to analysts’ expectations of $502.44 million. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The business’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.74 earnings per share. Equities research analysts forecast that IDEXX Laboratories, Inc. will post $3.18 EPS for the current fiscal year.
In other news, Chairman Jonathan W. Ayers sold 17,000 shares of the stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $154.54, for a total transaction of $2,627,180.00. Following the sale, the chairman now owns 1,039,034 shares of the company’s stock, valued at $160,572,314.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Jonathan W. Ayers sold 58,000 shares of the stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $155.00, for a total transaction of $8,990,000.00. Following the sale, the chairman now directly owns 1,043,034 shares in the company, valued at approximately $161,670,270. The disclosure for this sale can be found here. Insiders have sold 151,734 shares of company stock worth $23,436,626 in the last three months. Corporate insiders own 2.77% of the company’s stock.
A number of brokerages recently weighed in on IDXX. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $182.00 price objective for the company in a report on Wednesday, June 28th. Bank of America Corporation upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective for the company in a report on Wednesday, August 23rd. BidaskClub lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 5th. Stifel Nicolaus reiterated a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a report on Wednesday, August 2nd. Finally, CL King upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price objective for the company in a report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. IDEXX Laboratories has an average rating of “Hold” and an average price target of $174.00.
ILLEGAL ACTIVITY WARNING: “IDEXX Laboratories, Inc. (IDXX) Shares Bought by Goldman Sachs Group Inc.” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/idexx-laboratories-inc-idxx-shares-bought-by-goldman-sachs-group-inc/1601329.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.